JP2020531048A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020531048A5 JP2020531048A5 JP2020530735A JP2020530735A JP2020531048A5 JP 2020531048 A5 JP2020531048 A5 JP 2020531048A5 JP 2020530735 A JP2020530735 A JP 2020530735A JP 2020530735 A JP2020530735 A JP 2020530735A JP 2020531048 A5 JP2020531048 A5 JP 2020531048A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- hcdr3
- lcdr2
- lcdr1
- lcdr3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023049983A JP7564274B2 (ja) | 2017-08-18 | 2023-03-27 | 結合剤 |
| JP2024167571A JP7825015B2 (ja) | 2017-08-18 | 2024-09-26 | 結合剤 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1713298.6 | 2017-08-18 | ||
| GBGB1713298.6A GB201713298D0 (en) | 2017-08-18 | 2017-08-18 | Binding agents |
| GB1802595.7 | 2018-02-16 | ||
| GBGB1802595.7A GB201802595D0 (en) | 2018-02-16 | 2018-02-16 | Binding agents |
| GBGB1808570.4A GB201808570D0 (en) | 2018-05-24 | 2018-05-24 | Binding agents |
| GB1808570.4 | 2018-05-24 | ||
| PCT/GB2018/052347 WO2019034895A1 (en) | 2017-08-18 | 2018-08-17 | LIAISON AGENTS |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023049983A Division JP7564274B2 (ja) | 2017-08-18 | 2023-03-27 | 結合剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020531048A JP2020531048A (ja) | 2020-11-05 |
| JP2020531048A5 true JP2020531048A5 (https=) | 2021-09-30 |
| JP7256580B2 JP7256580B2 (ja) | 2023-04-12 |
Family
ID=63371721
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020530735A Active JP7256580B2 (ja) | 2017-08-18 | 2018-08-17 | 結合剤 |
| JP2023049983A Active JP7564274B2 (ja) | 2017-08-18 | 2023-03-27 | 結合剤 |
| JP2024167571A Active JP7825015B2 (ja) | 2017-08-18 | 2024-09-26 | 結合剤 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023049983A Active JP7564274B2 (ja) | 2017-08-18 | 2023-03-27 | 結合剤 |
| JP2024167571A Active JP7825015B2 (ja) | 2017-08-18 | 2024-09-26 | 結合剤 |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US10683350B2 (https=) |
| EP (2) | EP3668897B1 (https=) |
| JP (3) | JP7256580B2 (https=) |
| KR (1) | KR102781208B1 (https=) |
| CN (1) | CN111212852A (https=) |
| AU (2) | AU2018316742B2 (https=) |
| BR (1) | BR112020003306A2 (https=) |
| CA (1) | CA3072998A1 (https=) |
| ES (1) | ES2983651T3 (https=) |
| IL (1) | IL272643A (https=) |
| MX (1) | MX2020001873A (https=) |
| RU (1) | RU2020109544A (https=) |
| SG (1) | SG11202001425TA (https=) |
| WO (1) | WO2019034895A1 (https=) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111212852A (zh) | 2017-08-18 | 2020-05-29 | 超人肆有限公司 | 结合剂 |
| GB201804860D0 (en) | 2018-03-27 | 2018-05-09 | Ultrahuman Two Ltd | CD47 Binding agents |
| GB201906685D0 (en) | 2019-05-13 | 2019-06-26 | Ultrahuman Six Ltd | Activatable protein constructs and uses thereof |
| PH12021553197A1 (en) | 2019-06-19 | 2022-11-07 | Lepu Biopharma Co Ltd | Anti-cd47 antibodies and uses thereof |
| KR20240137107A (ko) | 2019-07-16 | 2024-09-19 | 길리애드 사이언시즈, 인코포레이티드 | Hiv 백신, 및 이의 제조 및 사용 방법 |
| JP2022548310A (ja) * | 2019-09-23 | 2022-11-17 | シートムエックス セラピューティクス，インコーポレイテッド | 抗ｃｄ４７抗体、活性化可能抗ｃｄ４７抗体、およびその使用方法 |
| ES2973832T3 (es) | 2019-10-18 | 2024-06-24 | Forty Seven Inc | Terapias combinadas para el tratamiento de síndromes mielodisplásicos y leucemia mieloide aguda |
| JP2022552748A (ja) | 2019-10-31 | 2022-12-19 | フォーティ セブン， インコーポレイテッド | 抗ｃｄ４７及び抗ｃｄ２０による血液癌の治療 |
| IL294032A (en) | 2019-12-24 | 2022-08-01 | Carna Biosciences Inc | Compounds that regulate diacylglycerol kinase |
| WO2021142331A1 (en) * | 2020-01-10 | 2021-07-15 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for modulation of genes associated with cardiac muscle disease |
| WO2021142269A1 (en) * | 2020-01-10 | 2021-07-15 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for modulation of genes associated with muscle atrophy |
| TWI890283B (zh) | 2020-02-14 | 2025-07-11 | 美商基利科學股份有限公司 | 結合ccr8之抗體及融合蛋白及其用途 |
| CN115916963A (zh) | 2020-03-27 | 2023-04-04 | 门德斯有限公司 | 白血病来源的经修饰细胞用于增强过继性细胞治疗的效力的离体用途 |
| EP4171617A1 (en) | 2020-06-30 | 2023-05-03 | Mendus B.V. | Use of leukemia-derived cells in ovarian cancer vaccines |
| CN111733162A (zh) * | 2020-07-01 | 2020-10-02 | 江苏莱森生物科技研究院有限公司 | 一种经基因修饰的cd47蛋白及其单克隆抗体和应用 |
| WO2022007947A1 (zh) * | 2020-07-10 | 2022-01-13 | 信达生物制药(苏州)有限公司 | 抗cd47抗体或其抗原结合片段和dna甲基化转移酶抑制剂的组合及其用途 |
| KR102757518B1 (ko) * | 2020-12-07 | 2025-01-21 | (주)이노베이션바이오 | Cd47에 특이적인 항체 및 이의 용도 |
| US12071481B2 (en) | 2020-12-23 | 2024-08-27 | D-10 Therapeutics, Inc. | Anti-CD47 antibodies and uses thereof |
| CA3212351A1 (en) | 2021-03-12 | 2022-09-15 | Mendus B.V. | Methods of vaccination and use of cd47 blockade |
| CN112794903B (zh) * | 2021-04-14 | 2021-06-25 | 广州市雷德生物科技有限公司 | 一种特异性结合IFN-γ的抗体及其应用 |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| AU2022299051B2 (en) | 2021-06-23 | 2025-03-13 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| JP7686091B2 (ja) | 2021-06-23 | 2025-05-30 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| JP7651018B2 (ja) | 2021-06-23 | 2025-03-25 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| MX2023014762A (es) | 2021-06-23 | 2024-01-15 | Gilead Sciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| JP2024527335A (ja) * | 2021-06-30 | 2024-07-24 | イノベイション バイオ カンパニー リミテッド | Ｃｄ４７に特異的なヒト化抗体およびそれを含むｃｄ４７関連疾患の予防または治療用医薬組成物 |
| WO2023070353A1 (en) * | 2021-10-27 | 2023-05-04 | Adagene Pte. Ltd. | Anti-cd47 antibodies and methods of use thereof |
| AU2022375782B2 (en) | 2021-10-28 | 2026-02-26 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| JP7787991B2 (ja) | 2021-10-29 | 2025-12-17 | ギリアード サイエンシーズ， インコーポレイテッド | Ｃｄ７３化合物 |
| US12122764B2 (en) | 2021-12-22 | 2024-10-22 | Gilead Sciences, Inc. | IKAROS zinc finger family degraders and uses thereof |
| KR20240123836A (ko) | 2021-12-22 | 2024-08-14 | 길리애드 사이언시즈, 인코포레이티드 | 이카로스 아연 핑거 패밀리 분해제 및 이의 용도 |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| CA3251615A1 (en) | 2022-01-31 | 2023-08-03 | Centessa Pharmaceuticals (Uk) Limited | Activable Bispecific Anti-CD47 and Anti-PD-L1 Proteins and Their Uses |
| WO2023178181A1 (en) | 2022-03-17 | 2023-09-21 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| KR20240165995A (ko) | 2022-03-24 | 2024-11-25 | 길리애드 사이언시즈, 인코포레이티드 | Trop-2 발현 암의 치료를 위한 병용요법 |
| WO2023191117A1 (ko) * | 2022-03-28 | 2023-10-05 | (주)이노베이션바이오 | 친화도가 성숙된 cd47에 특이적인 인간화 항체 |
| TWI876305B (zh) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| CR20240451A (es) | 2022-04-21 | 2024-12-04 | Gilead Sciences Inc | Compuestos de modulación de kras g12d |
| KR20250028371A (ko) | 2022-07-01 | 2025-02-28 | 길리애드 사이언시즈, 인코포레이티드 | Cd73 화합물 |
| CA3259040A1 (en) | 2022-07-12 | 2024-01-18 | Gilead Sciences, Inc. | HIV Immunogenic Polypeptides and Vaccines and Their Uses |
| WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
| AU2023409398A1 (en) | 2022-12-22 | 2025-06-05 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| AU2024252725A1 (en) | 2023-04-11 | 2025-11-06 | Gilead Sciences, Inc. | Kras modulating compounds |
| CR20250446A (es) | 2023-04-21 | 2025-12-02 | Gilead Sciences Inc | Inhibidores de prmt5 y usos de los mismos |
| AU2024306338A1 (en) | 2023-06-30 | 2026-01-08 | Gilead Sciences, Inc. | Kras modulating compounds |
| CN121620513A (zh) | 2023-07-26 | 2026-03-06 | 吉利德科学公司 | Parp7抑制剂 |
| KR20260046403A (ko) | 2023-07-26 | 2026-04-07 | 길리애드 사이언시즈, 인코포레이티드 | Parp7 저해제 |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250101042A1 (en) | 2023-09-08 | 2025-03-27 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250154172A1 (en) | 2023-11-03 | 2025-05-15 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025245003A1 (en) | 2024-05-21 | 2025-11-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| US20260098049A1 (en) | 2024-08-12 | 2026-04-09 | Gilead Sciences, Inc. | Kras modulating compounds |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2545166A1 (en) * | 2003-11-11 | 2005-05-19 | Chugai Seiyaku Kabushiki Kaisha | Humanized anti-cd47 antibody |
| DE102007001370A1 (de) * | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
| CN101231382B (zh) | 2008-02-26 | 2010-09-01 | 上海激光等离子体研究所 | 用于啁啾脉冲放大的光谱调制整形装置 |
| PT2569013T (pt) | 2010-05-14 | 2017-02-08 | Univ Leland Stanford Junior | Anticorpos monoclonais humanizados e quiméricos para cd47 |
| KR102100388B1 (ko) * | 2012-02-06 | 2020-04-13 | 인히브릭스, 인크. | Cd47 항체 및 그 사용 방법 |
| US20140140989A1 (en) | 2012-02-06 | 2014-05-22 | Inhibrx Llc | Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof |
| US9221908B2 (en) * | 2012-12-12 | 2015-12-29 | Vasculox, Inc. | Therapeutic CD47 antibodies |
| BR112015013431A2 (pt) | 2012-12-12 | 2017-11-14 | Vasculox Inc | anticorpos monoclonais ou respectivos fragmentos ligantes de antígenos, composição farmacêutica, e usos de anticorpo monoclonal ou respectivo fragmento ligante de antígenos |
| EP3221358B1 (en) * | 2014-11-18 | 2021-07-21 | Janssen Pharmaceutica, N.V. | Cd47 antibodies, methods, and uses |
| MX391051B (es) * | 2014-12-30 | 2025-03-21 | Celgene Corp | Anticuerpos anti-cd47 y usos de los mismos. |
| US10647756B2 (en) * | 2015-05-18 | 2020-05-12 | Pfizer Inc. | Humanized antibodies |
| RU2748401C2 (ru) * | 2015-09-18 | 2021-05-25 | Арч Онколоджи, Инк. | Терапевтические антитела к CD47 |
| PT3402820T (pt) * | 2016-01-11 | 2020-08-20 | Forty Seven Inc | Anticorpos monoclonais anti-cd47 quiméricos, de ratinho ou humanizados |
| CN111212852A (zh) | 2017-08-18 | 2020-05-29 | 超人肆有限公司 | 结合剂 |
| GB201804860D0 (en) | 2018-03-27 | 2018-05-09 | Ultrahuman Two Ltd | CD47 Binding agents |
-
2018
- 2018-08-17 CN CN201880066662.5A patent/CN111212852A/zh active Pending
- 2018-08-17 CA CA3072998A patent/CA3072998A1/en active Pending
- 2018-08-17 WO PCT/GB2018/052347 patent/WO2019034895A1/en not_active Ceased
- 2018-08-17 BR BR112020003306-5A patent/BR112020003306A2/pt unknown
- 2018-08-17 SG SG11202001425TA patent/SG11202001425TA/en unknown
- 2018-08-17 ES ES18759711T patent/ES2983651T3/es active Active
- 2018-08-17 RU RU2020109544A patent/RU2020109544A/ru unknown
- 2018-08-17 MX MX2020001873A patent/MX2020001873A/es unknown
- 2018-08-17 AU AU2018316742A patent/AU2018316742B2/en active Active
- 2018-08-17 JP JP2020530735A patent/JP7256580B2/ja active Active
- 2018-08-17 KR KR1020207007972A patent/KR102781208B1/ko active Active
- 2018-08-17 EP EP18759711.7A patent/EP3668897B1/en active Active
- 2018-08-17 EP EP24179206.8A patent/EP4435008A2/en not_active Withdrawn
-
2019
- 2019-08-19 US US16/543,884 patent/US10683350B2/en active Active
-
2020
- 2020-02-12 IL IL272643A patent/IL272643A/en unknown
- 2020-05-19 US US16/877,938 patent/US11370840B2/en active Active
-
2022
- 2022-06-24 US US17/849,101 patent/US20220332819A1/en not_active Abandoned
-
2023
- 2023-03-27 JP JP2023049983A patent/JP7564274B2/ja active Active
-
2024
- 2024-09-23 US US18/893,023 patent/US20250109202A1/en active Pending
- 2024-09-26 JP JP2024167571A patent/JP7825015B2/ja active Active
-
2025
- 2025-06-26 AU AU2025204808A patent/AU2025204808A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020531048A5 (https=) | ||
| RU2020109544A (ru) | Связывающие агенты | |
| JP2025000787A5 (https=) | ||
| JP7583707B2 (ja) | 抗ｃｄ４７抗体及びその応用 | |
| AU2016328204B2 (en) | Novel anti-mesothelin antibody and composition comprising the same | |
| JP2021519100A5 (https=) | ||
| JP2024522360A5 (https=) | ||
| JP2011518546A5 (https=) | ||
| JP2021513323A5 (https=) | ||
| EP4541813A2 (en) | Method of preparing ph-dependent antibodies | |
| RU2018145852A (ru) | Антитело против lag-3, его антигенсвязывающий фрагмент и их фармацевтическое применение | |
| TW201718657A (zh) | Ｐｄ－ｌ１抗體、其抗原結合片段及其醫藥用途 | |
| WO2014013075A2 (en) | Antibodies to highly conserved targets | |
| JP2020514277A5 (https=) | ||
| RU2019125975A (ru) | Связывающие агенты | |
| JP2012530496A5 (https=) | ||
| JP2010524435A5 (https=) | ||
| JP2020522280A5 (https=) | ||
| JP2016521715A (ja) | 抗ｔｗｅａｋｒ抗体およびその使用 | |
| JP2022533538A5 (https=) | ||
| JP2010509931A5 (https=) | ||
| CA3036912A1 (en) | Antibody specifically binding to pd-1 and functional fragment thereof | |
| JP2020522281A5 (https=) | ||
| JP7679399B2 (ja) | 抗ｆｌｔ３抗体及び組成物 | |
| JP2020505075A5 (https=) |